Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EPINuc

Financiado

Cerrado

Single Molecule Epigenetic Analysis of Plasma Isolated Nucleosomes for Colon Can...

Single Molecule Epigenetic Analysis of Plasma Isolated Nucleosomes for Colon Cancer Diagnostics The analysis of cell-free DNA (cfDNA) in plasma represents a rapidly advancing field in medicine, with developing methods aiming to utilize it for diagnostics of cancer and additional pathologies. Most liquid biopsy methods are se... ver más

31/08/2022

WEIZMANN

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-08-31

ERC-2020-POC: Call for proposals for ERC Proof of...

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

WEIZMANN

150.00K€ | Lider

CELAYA EMPARANZA Y GALDOS IN...

279.73K€ | Participante

Proyectos interesantes

EpiDetect

Medical Technol...

Data Science

2M€ Cerrado

RTC-2017-6685-1

Medical Technol...

Data Science

914K€ Cerrado

OR-HMC

Medical Technol...

Data Science

150K€ Cerrado

cfChIP

Medical Technol...

Data Science

3M€ Cerrado

EpiCblood

Medical Technol...

Data Science

1M€ Cerrado

MultiLQB-PC

Medical Technol...

Data Science

173K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 18 meses Fecha Inicio: 2021-02-12
Fecha Fin: 2022-08-31

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The analysis of cell-free DNA (cfDNA) in plasma represents a rapidly advancing field in medicine, with developing methods aiming to utilize it for diagnostics of cancer and additional pathologies. Most liquid biopsy methods are sequencing-based and provide limited information, usually relying on the detection of rare cancer-associated mutations. Therefore, they are costly and highly limited in their sensitivity. Importantly, blood cfDNA consists predominantly in the form of nucleosomes, which maintain their tissue-specific epigenetic modifications. Thus far, this rich epigenetic information has been inaccessible due to technical limitations. We developed EPINuc, a novel single-molecule multi-parametric-based assay to comprehensively profile the Epigenetics of Plasma Isolated Nucleosomes. Our approach is based on a technology we developed (Shema et al., Science), which allows high resolution profiling of combinatorial modification states on millions of individual nucleosomes by single-molecule imaging. EPINuc is unique in its capacity to generate multi-layered information from very limited liquid biopsy material. As proof of concept, we applied it to diagnose colorectal cancer (CRC), which is one of the most common cancers worldwide, necessitating expensive and invasive screening tests for all adults older than 50. Strikingly, EPINuc revealed significant differences in the epigenetic states and protein biomarkers’ levels between healthy individuals versus CRC patients. In this PoC, we will optimize EPINuc to generate holistic data from plasma-isolated nucleosomes that is expected to identify cancers early from a routine blood test, without the need for invasive measures. This technology has significant commercialization value for the liquid biopsy industry. We will develop a commercialization strategy and network with potential collaborators, customers and investors to spin out the innovation as a successful assay technology business.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores